These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 36223118

  • 1. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
    Frost MC, Zhang L, Kim HM, Lin LA.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2236298. PubMed ID: 36223118
    [Abstract] [Full Text] [Related]

  • 2. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Psychiatry; 2022 Oct 01; 79(10):981-992. PubMed ID: 36044198
    [Abstract] [Full Text] [Related]

  • 3. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA, Zhang L, Kim HM, Frost MC.
    Am J Psychiatry; 2022 Oct 01; 179(10):740-747. PubMed ID: 35899380
    [Abstract] [Full Text] [Related]

  • 4. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
    Nguyen B, Zhao C, Bailly E, Chi W.
    J Gen Intern Med; 2024 Jan 01; 39(1):95-102. PubMed ID: 37670069
    [Abstract] [Full Text] [Related]

  • 5. Overall and Telehealth Addiction Treatment Utilization by Age, Race, Ethnicity, and Socioeconomic Status in California After COVID-19 Policy Changes.
    Palzes VA, Chi FW, Metz VE, Sterling S, Asyyed A, Ridout KK, Campbell CI.
    JAMA Health Forum; 2023 May 05; 4(5):e231018. PubMed ID: 37204804
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM, Nielsen T, Hoeppner BB, Terplan M, Hansen H, Bernson D, Diop H, Bharel M, Krans EE, Selk S, Kelly JF, Wilens TE, Taveras EM.
    JAMA Netw Open; 2020 May 01; 3(5):e205734. PubMed ID: 32453384
    [Abstract] [Full Text] [Related]

  • 8. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
    Hawkins EJ, Malte CA, Hagedorn HJ, Gordon AJ, Williams EC, Trim RS, Blanchard BE, Lott A, Danner AN, Saxon AJ.
    J Addict Med; 2020 May 01; 18(3):240-247. PubMed ID: 38329814
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Telehealth and delivery of alcohol use disorder treatment in the Veterans Health Administration.
    Perumalswami PV, Adams MA, Frost MC, Holleman R, Kim HM, Zhang L, Lin LA.
    Alcohol Clin Exp Res (Hoboken); 2024 May 01; 48(5):944-954. PubMed ID: 38529689
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
    Cunningham CO, Khalid L, Deng Y, Torres-Lockhart K, Masyukova M, Thomas S, Zhang C, Lu T.
    J Subst Abuse Treat; 2022 Apr 01; 135():108641. PubMed ID: 34863608
    [Abstract] [Full Text] [Related]

  • 14. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A, Lu T, DiRenno F, Jadow B, Giovanniello A, Nahvi S, Cunningham C, Fox A.
    J Subst Abuse Treat; 2020 Dec 01; 119():108140. PubMed ID: 33138925
    [Abstract] [Full Text] [Related]

  • 15. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.
    Lin LA, Fortney JC, Bohnert ASB, Coughlin LN, Zhang L, Piette JD.
    J Subst Abuse Treat; 2022 Feb 01; 133():108492. PubMed ID: 34175175
    [Abstract] [Full Text] [Related]

  • 16. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
    Textor L, Ventricelli D, Aronowitz SV.
    Int J Drug Policy; 2022 Jul 01; 105():103703. PubMed ID: 35561484
    [Abstract] [Full Text] [Related]

  • 17. Telehealth for opioid use disorder: retention as a function of demographics and rurality.
    Williams AR, Aronowitz SV, Rowe C, Gallagher R, Behar E, Bisaga A.
    Am J Drug Alcohol Abuse; 2023 Mar 04; 49(2):260-265. PubMed ID: 36961998
    [Abstract] [Full Text] [Related]

  • 18. Patient Use and Clinical Practice Patterns of Remote Cardiology Clinic Visits in the Era of COVID-19.
    Yuan N, Pevnick JM, Botting PG, Elad Y, Miller SJ, Cheng S, Ebinger JE.
    JAMA Netw Open; 2021 Apr 01; 4(4):e214157. PubMed ID: 33818619
    [Abstract] [Full Text] [Related]

  • 19. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, Ilgen MA.
    Addiction; 2021 Jan 01; 116(1):96-104. PubMed ID: 32428386
    [Abstract] [Full Text] [Related]

  • 20. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA, Davenport M, Head M, Henke R, LeBeau LS, Gibson TB, Banducci AN, Sarpong A, Jayanthi S, Roth C, Camacho-Cook J, Meng F, Hyde J, Mulvaney-Day N, White M, Chen DC, Stein MD, Weisberg R.
    Drug Alcohol Depend; 2022 Dec 01; 241():109678. PubMed ID: 36368167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.